Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIMDNASDAQ:ALLRNASDAQ:BCTXNASDAQ:ENVB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDAinos$0.53+5.8%$0.56$0.40▼$1.07$10.46M2.2344,945 shs615,163 shsALLRAllarity Therapeutics$0.83-1.0%$0.96$0.61▼$14.25$12.11M-0.151.12 million shs149,068 shsBCTXBriacell Therap$3.12-1.3%$3.74$2.81▼$29.40$11.57M1.3550,810 shs77,453 shsENVBEnveric Biosciences$1.25-1.6%$1.27$1.01▼$11.55$2.99M0.53767,610 shs65,404 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDAinos+5.84%-9.95%-1.99%+5.54%-37.28%ALLRAllarity Therapeutics-0.97%-9.13%-20.58%-17.40%-93.76%BCTXBriacell Therap-1.27%-10.09%+6.12%-26.93%-85.95%ENVBEnveric Biosciences-1.57%-2.34%-3.85%-27.75%-88.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMDAinos0.8801 of 5 stars0.04.00.00.02.20.80.6ALLRAllarity Therapeutics0.8405 of 5 stars0.04.00.00.01.60.01.3BCTXBriacell Therap2.1068 of 5 stars3.52.00.00.03.30.00.6ENVBEnveric Biosciences2.0567 of 5 stars3.52.00.00.01.80.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMDAinos 0.00N/AN/AN/AALLRAllarity Therapeutics 0.00N/AN/AN/ABCTXBriacell Therap 3.00Buy$32.00925.64% UpsideENVBEnveric Biosciences 3.00Buy$10.00700.00% UpsideCurrent Analyst Ratings BreakdownLatest ENVB, AIMD, BCTX, and ALLR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2025BCTXBriacell TherapHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMDAinos$106.21K104.20N/AN/A$1.10 per share0.48ALLRAllarity TherapeuticsN/AN/AN/AN/A$1.62 per shareN/ABCTXBriacell TherapN/AN/AN/AN/A($2.20) per shareN/AENVBEnveric BiosciencesN/AN/AN/AN/A$2.35 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMDAinos-$14.86M-$1.29N/A∞N/AN/A-88.07%-48.60%8/4/2025 (Estimated)ALLRAllarity Therapeutics-$24.51MN/A0.00N/AN/AN/A-147.94%-90.33%8/4/2025 (Estimated)BCTXBriacell Therap-$4.79M-$5.03N/AN/AN/AN/A-1,370.20%-227.30%N/AENVBEnveric Biosciences-$9.57M-$38.38N/AN/AN/AN/A-250.28%-195.57%8/11/2025 (Estimated)Latest ENVB, AIMD, BCTX, and ALLR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/13/2025Q3 2025BCTXBriacell Therap-$1.76-$1.64+$0.12-$1.64N/AN/A5/14/2025Q1 2025ENVBEnveric Biosciences-$3.45-$1.22+$2.23-$1.22N/AN/A5/13/2025Q1 2025ALLRAllarity Therapeutics-$8.10-$0.25+$7.85-$0.25N/AN/A5/12/2025Q1 2025AIMDAinosN/A-$0.21N/A-$0.21N/A$0.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMDAinosN/AN/AN/AN/AN/AALLRAllarity TherapeuticsN/AN/AN/AN/AN/ABCTXBriacell TherapN/AN/AN/AN/AN/AENVBEnveric BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMDAinos0.842.001.91ALLRAllarity TherapeuticsN/A2.662.66BCTXBriacell TherapN/A1.371.37ENVBEnveric BiosciencesN/A4.084.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMDAinosN/AALLRAllarity Therapeutics11.53%BCTXBriacell Therap15.42%ENVBEnveric Biosciences13.82%Insider OwnershipCompanyInsider OwnershipAIMDAinos10.39%ALLRAllarity Therapeutics0.01%BCTXBriacell Therap5.73%ENVBEnveric Biosciences3.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMDAinos4020.76 million18.61 millionNot OptionableALLRAllarity Therapeutics1015.08 million15.08 millionNot OptionableBCTXBriacell Therap83.71 million3.50 millionOptionableENVBEnveric Biosciences202.47 million2.39 millionNot OptionableENVB, AIMD, BCTX, and ALLR HeadlinesRecent News About These CompaniesEnveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric DisordersJune 10, 2025 | businesswire.comEnveric Biosciences secures patent for sleep disorder moleculesJune 4, 2025 | investing.comEnveric Biosciences reports positive preclinical results for depression drug candidateMay 29, 2025 | gulfshorebusiness.comEnveric Biosciences announces results from EB-003 trialMay 29, 2025 | finance.yahoo.comEnveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003May 28, 2025 | finance.yahoo.comEnveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative DiseaseMay 21, 2025 | finance.yahoo.comEnveric Biosciences Reports First Quarter 2025 Financial and Corporate ResultsMay 14, 2025 | businesswire.comEnveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024March 31, 2025 | bakersfield.comEnveric Biosciences Participating in BIO-Europe Spring®March 17, 2025 | businesswire.comEnveric Biosciences to auction PsyAI trademark portfolioMarch 9, 2025 | uk.investing.comEnveric Biosciences launches RFP solicitation process for PsyAI trademarkMarch 6, 2025 | markets.businessinsider.comEnveric Biosciences CEO Issues Letter to ShareholdersFebruary 27, 2025 | businesswire.comThis Biotech Soared On Key AnnouncementFebruary 26, 2025 | msn.comBiotech Stock Enveric Biosciences (NASDAQ: ENVB) Soars on Patent NewsFebruary 26, 2025 | investorideas.comEnveric Biosciences Unveils EVM401 Series of Compounds with New U.S. PatentFebruary 25, 2025 | businesswire.comPsychedelic: Exclusive talk with biotech company Enveric BiosciencesFebruary 20, 2025 | markets.businessinsider.comENVB stock touches 52-week low at $1.51 amid market challengesFebruary 11, 2025 | msn.comEnveric Biosciences unit in licensing pacts with Restoration BiologicsFebruary 5, 2025 | markets.businessinsider.comEnveric Biosciences Down Sharply After Public OfferingJanuary 31, 2025 | marketwatch.comEnveric’s stock split leads to quick $5M raise but shares slideJanuary 31, 2025 | greenmarketreport.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeENVB, AIMD, BCTX, and ALLR Company DescriptionsAinos NASDAQ:AIMD$0.53 +0.03 (+5.84%) As of 06/17/2025 04:00 PM EasternAinos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.Allarity Therapeutics NASDAQ:ALLR$0.83 -0.01 (-0.97%) Closing price 06/17/2025 04:00 PM EasternExtended Trading$0.82 -0.01 (-0.61%) As of 04:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.Briacell Therap NASDAQ:BCTX$3.12 -0.04 (-1.27%) Closing price 06/17/2025 04:00 PM EasternExtended Trading$3.02 -0.10 (-3.04%) As of 06/17/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.Enveric Biosciences NASDAQ:ENVB$1.25 -0.02 (-1.57%) Closing price 06/17/2025 04:00 PM EasternExtended Trading$1.24 -0.01 (-0.48%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analyst Downgrades Joby, But Overlooks Major Regulatory Wins Applied Digital: Now the High-Stakes Race to Build Begins Zscaler Upgraded: Wall Street Forecasts 26% More Upside U.S. Steel Stock Burns the Bears With Surprise Upside Move Is CrowdStrike Stock Set to Break Out or Cool Off? New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 The Bottom Is in for Powerfleet: An Intelligent Time to Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
